BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 3925865)

  • 1. Activities of antiplasmin and antiplasminogen activator in serous middle ear effusions.
    Hamaguchi Y; Ohi M; Sakakura Y; Miyoshi Y
    Ann Otol Rhinol Laryngol; 1985; 94(3):293-6. PubMed ID: 3925865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interfering factors in the assay of plasminogen activators by the fibrin plate method. Occurrence of different inhibitors against tissue plasminogen activator and urokinase.
    Wijngaards G
    Thromb Haemost; 1979 May; 41(3):590-600. PubMed ID: 111368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
    Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
    J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human articular cartilage contains an inhibitor of plasminogen activator.
    Yamada H; Stephens RW; Nakagawa T; McNicol D
    J Rheumatol; 1988 Jul; 15(7):1138-43. PubMed ID: 3139880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antifibrinolytic activity in middle ear effusion.
    Hamaguchi Y; Sakakura Y; Ukai K; Ohi M; Miyoshi Y
    ORL J Otorhinolaryngol Relat Spec; 1984; 46(5):235-41. PubMed ID: 6237294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The plasma inhibitors of plasminogen activator, studied by a zymographic technique.
    Booth NA; Anderson JA; Bennett B
    Thromb Res; 1985 May; 38(3):261-7. PubMed ID: 3161209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-traumatic plasminogenesis in intraarticular exudate in the knee joint.
    Rość D; Powierza W; Zastawna E; Drewniak W; Michalski A; Kotschy M
    Med Sci Monit; 2002 May; 8(5):CR371-8. PubMed ID: 12011780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma.
    Verheijen JH; Chang GT; Kluft C
    Thromb Haemost; 1984 Jul; 51(3):392-5. PubMed ID: 6437006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome.
    Vaziri ND; Gonzales EC; Shayestehfar B; Barton CH
    J Lab Clin Med; 1994 Jul; 124(1):118-24. PubMed ID: 7518491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amiloride selectively inhibits the urokinase-type plasminogen activator.
    Vassalli JD; Belin D
    FEBS Lett; 1987 Apr; 214(1):187-91. PubMed ID: 3106085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of a plasmin A-chain/t-PA B-chain hybrid enzyme with plasma inhibitors in vivo and in vitro.
    Wilson S; Chamberlain P; Dodd I; Esmail A; Robinson JH
    Thromb Haemost; 1990 Jun; 63(3):459-63. PubMed ID: 1698316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complexes between tissue-type plasminogen activator and proteinase inhibitors in human plasma, identified with an immunoradiometric assay.
    Rijken DC; Juhan-Vague I; Collen D
    J Lab Clin Med; 1983 Feb; 101(2):285-94. PubMed ID: 6681624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma component of middle ear effusion evaluated by prekallikrein level.
    Hamaguchi Y; Sakakura Y; Majima Y; Ukai K; Miyoshi Y
    ORL J Otorhinolaryngol Relat Spec; 1985; 47(3):145-50. PubMed ID: 3846864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephrotic syndrome with renal vein thrombosis: pathogenetic importance of a plasmin inhibitor (alpha 2-antiplasmin).
    Du XH; Glas-Greenwalt P; Kant KS; Allen CM; Hayes S; Pollak VE
    Clin Nephrol; 1985 Oct; 24(4):186-91. PubMed ID: 3933871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Nitric oxide and cytokines in otitis media with effusion].
    Lin G; Huang W; Jiang H; Wang J
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 2000 Feb; 35(1):23-5. PubMed ID: 12768683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation of peptides with anti-urokinase activity from the human placenta.
    Uszynski M
    Thromb Haemost; 1980 Feb; 42(5):1411-6. PubMed ID: 6768150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of castration on plasminogen activator activities and plasminogen activator inhibitor type 1 in the rat ventral prostate.
    Wilson MJ; Ludowese C; Sinha AA; Estensen RD
    Prostate; 1996 Apr; 28(4):239-50. PubMed ID: 8602400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Borrelia burgdorferi-bound fibrinolytic enzymes by alpha2-antiplasmin, PAI-1 and PAI-2.
    Perides G; Noring R; Klempner MS
    Biochem Biophys Res Commun; 1996 Feb; 219(3):690-5. PubMed ID: 8645243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purification and characterization of an inhibitor of plasminogen activator released by rat mammary adenocarcinoma cells.
    Grant AJ; Ramshaw IA; Badenoch-Jones P; Eichner RD; Hunt NH
    Eur J Biochem; 1986 Feb; 154(3):635-41. PubMed ID: 3081343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies of fibrinolytic activity of uremic and longterm hemodialytic patients with special reference to fibrinolytic inhibitor.
    Homma T; Ichikawa T
    Biochem Exp Biol; 1979; 15(3):229-36. PubMed ID: 122165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.